SC14D9C

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14D-9

SOLICITATION/RECOMMENDATION STATEMENT

UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934

ABIOMED, INC.

(Name of Subject Company)

ABIOMED, INC.

(Name of Person(s) Filing Statement)

Common stock, par value $0.01 per share

(Title of Class of Securities)

003654100

(CUSIP Number of Class of Securities)

Marc A. Began

Vice President, General Counsel and Secretary

ABIOMED, Inc.

22 Cherry Hill Drive

Danvers, Massachusetts 01923

(978) 646-1400

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of the Person(s) Filing Statement)

With copies to:

Robert W. Downes

Matthew G. Hurd

Sullivan & Cromwell LLP

125 Broad Street

New York, New York 10004

(212) 558-4000

☒ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

This Schedule 14D-9 filing consists of certain communications relating to the proposed acquisition of ABIOMED, Inc., a Delaware corporation (the “Company”), by Johnson & Johnson, a New Jersey corporation (“Parent”), and Athos Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), pursuant to the terms and subject to the conditions of an Agreement and Plan of Merger, dated as of October 31, 2022, by and among the Company, Parent and Merger Sub.

1. Exhibit 99.1: Letter from Mike Minogue, Chairman, President and Chief Executive Officer, included in monthly all-employee Newsletter, dated November 7, 2022.

2. Exhibit 99.2: German translation of Letter from Mike Minogue, Chairman, President and Chief Executive Officer, included in monthly all-employee Newsletter, dated November 7, 2022.

3. Exhibit 99.3: Japanese translation of Letter from Mike Minogue, Chairman, President and Chief Executive Officer, included in monthly all-employee Newsletter, dated November 7, 2022.

Items #1-3 list above were first used or made available on November 7, 2022.

ADDITIONAL INFORMATION AND WHERE TO FIND IT

The tender offer described in this communication has not yet commenced. This communication is neither an offer to purchase nor a solicitation of an offer to sell shares of the Company. At the time the offer is commenced, Parent and Merger Sub will file a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission (the “SEC”), and the Company will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. The Company stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, as they may be amended from time to time, when they become available because they will contain important information that should be read carefully before any decision is made with respect to the tender offer. These materials will be sent free of charge to all stockholders of the Company. In addition, all of these materials (and all other materials filed by the Company with the SEC) will be available at no charge from the SEC through its website at www.sec.gov. Investors and security holders may also obtain free copies of the documents filed with the SEC by the Company at https://investors.abiomed.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. Forward-looking statements include, among other things, statements regarding the potential benefits of the proposed transaction; the prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for the Company’s business; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; any potential strategic benefits, synergies or opportunities expected as a result of the proposed transaction; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.

Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; the risk that the proposed transaction may not be completed in a timely manner or at all; uncertainties as to how many of the Company’s stockholders will tender their stock in the offer; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the effect of this announcement or pendency of the proposed transaction on the Company’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, its business generally or its stock price; risks related to diverting management’s attention from the Company’s ongoing business operations; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the potential that the strategic benefits, synergies or opportunities expected from the proposed acquisition may not be realized or may take longer to realize than expected; the successful integration of the Company into Parent subsequent to the closing of the transaction and the timing of such integration; other business effects, including the effects of industry, economic or political conditions outside of the Company’s control; transaction costs; and other risks and uncertainties detailed from time to time in documents filed with the SEC by the Company, including the Company’s current annual report on Form 10-K on file with the SEC, as well as the Schedule 14D-9 to be filed by the Company and the tender offer documents to be filed by Parent and Merger Sub. The effects of the COVID-19 pandemic may give rise to risks that are currently unknown or amplify the risks associated with many of these factors.

The Company is providing the information in this filing as of this date and assumes no obligation to update any forward-looking statements as a result of new information, future developments or otherwise, except as required by law.

Exhibit No.	Description
99.1	Letter from Mike Minogue, Chairman, President and Chief Executive Officer, included in monthly all-employee Newsletter, dated November 7, 2022.
99.2	German translation of Letter from Letter from Mike Minogue, Chairman, President and Chief Executive Officer, included in monthly all-employee Newsletter, dated November 7, 2022.
99.3	Japanese translation of Letter from Mike Minogue, Chairman, President and Chief Executive Officer, included in monthly all-employee Newsletter, dated November  7, 2022.

EX-99.1

Exhibit 99.1

The following is an excerpt from the November edition of the Company Monthly Newsletter, which was disseminated to all employees on November 7, 2022.

Letter From Mike Minogue

Chairman, President and Chief Executive Officer

Hello Everyone,

What an incredible week for Abiomed. Last Tuesday, Johnson & Johnson, one of the biggest companies in MedTech, announced it will be bringing heart recovery all over the world. You created the field of heart recovery. Congratulations!

I am also excited for our special culture to thrive under Johnson & Johnson’s ownership. I am confident we will sustain our winning culture because YOU are the stewards of our culture.

Our Four Principles will continue to describe WHAT we do. We will remain the best in the world at recovering hearts and saving lives, leading in technology and innovation, growing shareholder value, and sustaining our winning culture. Our Heartbeat Operating Procedures will continue to describe HOW we do things. Each of you is empowered to lead, manage, adapt and execute. We pursue perfection. We innovate. We pilot with speed, conduct After Action Reviews, and apply the learnings.

And, with every decision we make, we will always put Patients First. Our patients and customers are the motivation for all that we do and achieving our mission is dependent on their well-being. We work hard, have faith in each other, and have fun celebrating the patient success stories.

One success story I would like to celebrate is Stephen Hanns, a 39-year-old police officer from Chelsea, Alabama. In August 2022, Stephen and his fiancé, Sydney (seen in the photos above) were looking at wedding venues when he began experiencing shortness of breath and tightness in his chest. A few days later, Stephen became nauseous and experienced severe chest pain. Sydney drove him to Grandview Medical Center in Birmingham, Alabama, where tests revealed he had severe mitral regurgitation, a reduced ejection fraction of 15 percent, and was in cardiogenic shock due to cardiomyopathy.

Dr. William Black inserted Impella CP to allow Stephen’s heart to rest. After one day of support, Dr. Black and cardiothoracic surgeon Dr. John Casterline escalated Stephen’s support to Impella 5.5 and placed VA-ECMO to oxygenate his body. He was then transferred to UAB Hospital for escalated care and a possible heart transplant.

Once at UAB, Stephen’s medical team performed an SVT ablation and days later, his heart function dramatically improved. Following six days of support, ECMO was weaned and removed. After 11 days of Impella support, Impella 5.5 was explanted. While recovering in the ICU, Stephen and Sydney officially wed during a small ceremony in his hospital room. (photo below)

Less than one month after entering the hospital, Stephen went home with his native heart and his new bride. Today, Stephen and Sydney are planning their wedding reception and a honeymoon in Key West, Florida. Thank you to Team Birmingham South for helping to recover Stephen’s heart.

Patients like Stephen are our WHY. They inspire us to do everything possible to make heart recovery the global standard of care.

Patients First!

Mike

Additional Information and Where to Find it

The tender offer described in this communication has not yet commenced. This communication is neither an offer to purchase nor a solicitation of an offer to sell shares of ABIOMED, Inc. At the time the offer is commenced, Johnson & Johnson and its merger subsidiary, Athos Merger Sub, Inc., will file a Tender Offer Statement on Schedule TO with the U.S. Securities and

Exchange Commission, and ABIOMED, Inc. will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. ABIOMED, Inc. stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, as they may be amended from time to time, when they become available because they will contain important information that should be read carefully before any decision is made with respect to the tender offer. These materials will be sent free of charge to all stockholders of ABIOMED, Inc. In addition, all of these materials (and all other materials filed by ABIOMED, Inc. with the SEC) will be available at no charge from the SEC through its website at www.sec.gov. Investors and security holders may also obtain free copies of the documents filed with the SEC by ABIOMED, Inc. at https://investors.abiomed.com/investors/financials/sec-filings/default.aspx.

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. Forward-looking statements include, among other things, statements regarding the potential benefits of the proposed transaction; the prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for ABIOMED’s business; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; any potential strategic benefits, synergies or opportunities expected as a result of the proposed transaction; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.

Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; the risk that the proposed transaction may not be completed in a timely manner or at all; uncertainties as to how many of ABIOMED’s stockholders will tender their stock in the offer; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the effect of this announcement or pendency of the proposed transaction on the ABIOMED’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, its business generally or its stock price; risks related to diverting management’s attention from ABIOMED’s ongoing business operations; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the potential that the strategic benefits, synergies or opportunities expected from the proposed acquisition may not be realized or may take longer to realize than expected; the successful integration of ABIOMED into Johnson & Johnson subsequent to the closing of the transaction and the timing of such integration; other business effects, including the effects of industry, economic or political conditions outside of ABIOMED’s control; transaction costs; and other risks and uncertainties detailed from time to time in documents filed with the Securities and Exchange Commission (“SEC”) by ABIOMED, including ABIOMED’s current annual report on Form 10-K on file with the SEC, as well as the Schedule 14D-9 to be filed by ABIOMED and the tender offer documents to be filed by Johnson & Johnson and Athos Merger Sub, Inc. The effects of the COVID-19 pandemic may give rise to risks that are currently unknown or amplify the risks associated with many of these factors.

ABIOMED is providing the information in this filing as of this date and assumes no obligation to update any forward-looking statements as a result of new information, future developments or otherwise.

EX-99.2

Exhibit 99.2

The following is an excerpt from the German translation of the November edition of the Company Monthly Newsletter, which was disseminated to all employees on November 7, 2022.

Brief von Mike Minogue

Vorsitzender, Präsident und Chief Executive Officer

Hallo zusammen,

was für eine unglaubliche Woche für Abiomed. Letzten Dienstag kündigte Johnson & Johnson, eines der größten Unternehmen der Medizintechnik an, dass es die Herzgenesung in die ganze Welt bringen wird. Ihr habt das Feld der Herzregeneration erschaffen. Herzlichen Glückwunsch!

Ich freue mich auch darauf, dass unsere besondere Kultur unter der Eigentümerschaft von Johnson & Johnson gedeihen wird. Ich bin zuversichtlich, dass wir unsere erfolgreiche Kultur beibehalten werden, denn IHR seid die Erschaffer und Bewahrer unserer Kultur.

Unsere vier Grundsätze werden weiterhin beschreiben, WAS wir tun. Wir werden weiterhin die Besten der Welt sein, wenn es darum geht, Herzen zu retten und Leben zu erhalten, führend in Technologie und Innovation zu sein, den Wert für unsere Aktionäre zu steigern und unsere erfolgreiche Kultur zu erhalten. Unsere „Heartbeat Operating Procedures“ werden weiterhin beschreiben, WIE wir Dinge tun. Jeder von uns ist aufgerufen zu führen, zu managen, anzupassen und auszuführen. Wir streben nach Perfektion. Wir sind innovativ. Wir führen Pilotprojekte mit hoher Geschwindigkeit durch, führen After Action Reviews durch und wenden die gewonnenen Erkenntnisse an.

Und bei jeder Entscheidung, die wir treffen, stehen die Patienten immer an erster Stelle. Unsere Patienten und Kunden sind die Motivation für alles, was wir tun. Das Erreichen unserer Mission hängt von ihrem Wohlergehen ab. Wir arbeiten hart, vertrauen uns gegenseitig und haben Spaß daran, die Erfolge unserer Patienten zu feiern.

Eine Erfolgsgeschichte, die ich gerne teilen möchte, ist Stephen Hanns, ein 39-jähriger Polizeibeamter aus Chelsea, Alabama. Im August 2022 sahen sich Stephen und seine Verlobte Sydney (auf den Fotos oben) Hochzeitslocations an, als er Kurzatmigkeit und ein Engegefühl in der Brust verspürte. Einige Tage später wurde Stephen übel und er hatte starke Schmerzen in der Brust. Sydney fuhr ihn ins Grandview Medical Center in Birmingham, Alabama, wo Tests ergaben, dass er eine schwere Mitralinsuffizienz und eine reduzierte Auswurffraktion von 15 Prozent hatte und sich aufgrund einer Kardiomyopathie im kardiogenen Schock befand.

Dr. William Black setzte Impella CP ein, damit Stephens Herz sich erholen konnte. Nach einem Tag der Unterstützung erhöhten Dr. Black und der Herz-Thorax-Chirurg Dr. John Casterline Stephens Unterstützung auf Impella 5,5 und setzten VA-ECMO ein, um seinen Körper mit Sauerstoff zu versorgen. Anschließend wurde er zur weiteren Behandlung und für eine mögliche Herztransplantation ins UAB Hospital verlegt.

In der UAB führte Stephens medizinisches Team eine SVT-Ablation durch, und Tage später verbesserte sich seine Herzfunktion dramatisch. Nach sechs Tagen der Unterstützung wurde die ECMO abgesetzt und entfernt. Nach 11 Tagen der Impella-Unterstützung wurde die Impella 5.5 explantiert. Während er sich auf der Intensivstation erholte, heirateten Stephen und Sydney offiziell während einer kleinen Zeremonie in seinem Krankenhauszimmer (Foto unten).

Weniger als einen Monat nach seiner Einlieferung ins Krankenhaus kehrte Stephen mit seinem natürlichen Herzen und seiner neuen Braut nach Hause zurück. Heute planen Stephen und Sydney ihren Hochzeitsempfang und ihre Flitterwochen in Key West, Florida. Vielen Dank an das Team Birmingham South für die Hilfe bei der Wiederherstellung von Stephens Herz.

Patienten wie Stephen sind unser WARUM. Sie spornen uns an, alles zu tun, um die Regeneration des Herzens zum weltweiten Standard der Versorgung zu machen.

Die Patienten stehen an erster Stelle!

Patients First!

Mike

Additional Information and Where to Find it

The tender offer described in this communication has not yet commenced. This communication is neither an offer to purchase nor a solicitation of an offer to sell shares of ABIOMED, Inc. At the time the offer is commenced, Johnson & Johnson and its merger subsidiary, Athos Merger Sub, Inc., will file a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission, and ABIOMED, Inc. will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. ABIOMED, Inc. stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, as they may be amended from time to time, when they become available because they will contain important information that should be read carefully before any decision is made with respect to the tender offer. These materials will be sent free of charge to all stockholders of ABIOMED, Inc. In addition, all of these materials (and all other materials filed by ABIOMED, Inc. with the SEC) will be available at no charge from the SEC through its website at www.sec.gov. Investors and security holders may also obtain free copies of the documents filed with the SEC by ABIOMED, Inc. at https://investors.abiomed.com/investors/financials/sec-filings/default.aspx.

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. Forward-looking statements include, among other things, statements regarding the potential benefits of the proposed transaction; the prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for ABIOMED’s business; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; any potential strategic benefits, synergies or opportunities expected as a result of the proposed transaction; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.

Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; the risk that the proposed transaction may not be completed in a timely manner or at all; uncertainties as to how many of ABIOMED’s stockholders will tender their stock in the offer; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the effect of this announcement or pendency of the proposed transaction on the ABIOMED’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, its business generally or its stock price; risks related to diverting management’s attention from ABIOMED’s ongoing business operations; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the potential that the strategic benefits, synergies or opportunities expected from the proposed acquisition may not be realized or may take longer to realize than expected; the successful integration of ABIOMED into Johnson & Johnson subsequent to the closing of the transaction and the timing of such integration; other business effects, including the effects of industry, economic or political conditions outside of ABIOMED’s control; transaction costs; and other risks and uncertainties detailed from time to time in documents filed with the Securities and Exchange Commission (“SEC”) by ABIOMED, including ABIOMED’s current annual report on Form 10-K on file with the SEC, as well as the Schedule 14D-9 to be filed by ABIOMED and the tender offer documents to be filed by Johnson & Johnson and Athos Merger Sub, Inc. The effects of the COVID-19 pandemic may give rise to risks that are currently unknown or amplify the risks associated with many of these factors.

ABIOMED is providing the information in this filing as of this date and assumes no obligation to update any forward-looking statements as a result of new information, future developments or otherwise.

EX-99.3

Exhibit 99.3

The following is an excerpt from the Japanese translation of the November edition of the Company Monthly Newsletter, which was disseminated to all employees on November 7, 2022.

マイク・ミノーグからのメッセージ

会長、社長 兼 最高経営責任者

皆さん、こんにちは。

先週はアビオメッドにとって一生記憶に残る一週間でした。 先週の火曜日、医療機器最大手企業であるジョンソン・エンド・ジョンソンが、心機能回復を世界中に広めるということを発表しました。ハートリカバリーの分野を開拓したのは他でもない皆さんです。心より感謝申し上げます！

また、ジョンソン・エンド・ジョンソンのオーナーシップのもと、私たちの特別なカルチャーがさらに発展していくことに期待しています。 私たちの文化を支えているのは、皆さんであると確信しています。

アビオメッドの４原則は、私たちが何をべきかを説明し続けます。私たちは、心臓の回復と人命の救助、テクノロジーとイノベーションをリードする、株主価値を最大化させる、そしてウィニングカルチャーを持続させる点において、世界一の企業であり続けるでしょう。心臓の鼓動である業務手順は、私たちがどのように物事を行うかを説明するものです。 私たち一人ひとりが、リードし、管理し、適応し、実行する権限を与えられています。 私たちは完璧を追求します。私たちは革新します。私たちはスピード感を持って行動し、AARを行い、学んだことを実行に移します。

そして、私たちが行うすべての決定において、常に患者さんを第一に考えます。 患者さんと顧客は、私たちのすべての行動の原動力であり、私たちの使命の達成は、彼らの幸福につながります。 私たちは懸命に働き、お互いを信頼し、患者さんのハートリカバリーストーリーを皆で祝います。

私が祝福したいハートリカバリーストーリーは、アラバマ州チェルシーに住む 39歳の警察官であるステファン・ハンズさんです。 2022年8月、ステファンさんは婚約者のシドニーさん（上の写真）と共に結婚式場を見学していたところ、息切れと胸の締めつけを感じるようになりました。 数日後、ステファンさんは吐き気を催し、激しい胸の痛みを経験しました。 シドニーさんの運転する車でアラバマ州バーミンガムのグランドビューメディカルセンターに運ばれ、検査の結果、重度の僧帽弁閉鎖不全症、駆出率 15％の低下、心筋症による心原性ショック状態であることが判明しました。

ウィリアム・ブラック医師は、ステファンさんの心臓を休ませるためにImpella CPを挿入しました。 1日後、ブラック医師と胸部外科医のジョン・キャスターライン医師は、ステファンさんのサポートを Impella 5.5にエスカレートさせ、体内に酸素を供給するために VA-ECMOを使用した。 その後、ステファンさんはUAB病院に移され、より高度な治療と心臓移植の可能性が検討されました。

UABでは、医療チームがSVTアブレーションを行い、その数日後、彼の心機能は劇的に改善されました。 6日間のサポートの後、ECMOから離脱しました。 11 日間のImpellaによるサポートの後、Impella 5.5は抜去されました。 ICUでの療養

中、ステファンさんとシドニーさんは病室で小さな結婚式を挙げ、正式に結婚しました。 (写真下)

入院から1カ月も経たないうちに、ステファンさんはは自己心機能と新しい花嫁と共に家に帰ることができました。 現在、ステファンさんとシドニーさんは結婚披露宴とフロリダ州キーウェストでの新婚旅行を計画しています。 ステファンさんの心臓を回復させてくれたチーム・バーミンガム・サウスの皆さん、ありがとうございました。

ステファンさんのような患者さんは、私たちの WHY（なぜ）です。彼らは、心臓の回復を世界の標準治療にするためにできる限りのことをするよう、私たちを鼓舞してくれる存在です。

患者さん第一！

マイク・ミノーグ

マイクへのメッセージはこちらからお送りください

Additional Information and Where to Find it

The tender offer described in this communication has not yet commenced. This communication is neither an offer to purchase nor a solicitation of an offer to sell shares of ABIOMED, Inc. At the time the offer is commenced, Johnson & Johnson and its merger subsidiary, Athos Merger Sub, Inc., will file a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission, and ABIOMED, Inc. will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. ABIOMED, Inc. stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, as they may be amended from time to time, when they become available because they will contain important information that should be read carefully before any decision is made with respect to the tender offer. These materials will be sent free of charge to all stockholders of ABIOMED, Inc. In addition, all of these materials (and all other materials filed by ABIOMED, Inc. with the Securities and Exchange Commission (“SEC”)) will be available at no charge from the SEC through its website at www.sec.gov [content.abiomed.com]. Investors and security holders may also obtain free copies of the documents filed with the SEC by ABIOMED, Inc. at https://investors.abiomed.com/investors/financials/sec-filings/default.aspx [content.abiomed.com].

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. Forward-looking statements include, among other things, statements regarding the potential benefits of the proposed transaction; the prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for ABIOMED’s business; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; any potential strategic benefits, synergies or opportunities expected as a result of the proposed transaction; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.

Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; the risk that the proposed transaction may not be completed in a timely manner or at all; uncertainties as to how many of ABIOMED’s stockholders will tender their stock in the offer; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the effect of this announcement or pendency of the proposed transaction on the ABIOMED’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, its business generally or its stock price; risks related to diverting management’s attention from ABIOMED’s ongoing business operations; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the potential that the

strategic benefits, synergies or opportunities expected from the proposed acquisition may not be realized or may take longer to realize than expected; the successful integration of ABIOMED into Johnson & Johnson subsequent to the closing of the transaction and the timing of such integration; other business effects, including the effects of industry, economic or political conditions outside of ABIOMED’s control; transaction costs; and other risks and uncertainties detailed from time to time in documents filed with the SEC by ABIOMED, including ABIOMED’s current annual report on Form 10-K on file with the SEC, as well as the Schedule 14D-9 to be filed by ABIOMED and the tender offer documents to be filed by Johnson & Johnson and Athos Merger Sub, Inc. The effects of the COVID-19 pandemic may give rise to risks that are currently unknown or amplify the risks associated with many of these factors.

ABIOMED is providing the information in this filing as of this date and assumes no obligation to update any forward-looking statements as a result of new information, future developments or otherwise.